Display options
Share it on

Basic Res Cardiol. 1987 Jan-Feb;82(1):57-65. doi: 10.1007/BF01907053.

Effect of complement depletion on O2 supply and consumption in ischemic dog myocardium.

Basic research in cardiology

G J Grover, H R Weiss

PMID: 3593182 DOI: 10.1007/BF01907053

Abstract

The purpose of this study was to determine whether depletion of serum complement can decrease the severity of an ischemic episode by improving regional O2 supply and consumption parameters in the ischemic region of the heart. Fourteen anesthetized dogs with serum complement intact or depleted (100 U/kg cobra venom factor given 8 hrs before) were subjected to left anterior descending coronary artery (LAD) occlusion for 6 hrs. Myocardial blood flows were determined before and 6 hrs after LAD occlusion using radioactive microspheres. Regional arterial and venous O2 saturations were determined using microspectrophotometry. In control animals, flow decreased from 122 +/- 42 to 13 +/- 14 ml/min/100 g (mean +/- SD) in the occluded LAD region. With complement depletion, LAD occlusion resulted in a flow reduction in the ischemic region (38 +/- 29 ml/min/100 g), but to a lesser degree than seen in the same region in control animals, especially in the subendocardium. O2 consumption was decreased in the ischemic region of both treatment groups, though O2 consumption was higher in this region in complement depleted animals compared to the values in control animals. The O2 supply/consumption ratio was decreased similarly in the ischemic region of control and complement depleted groups. Thus, with complement depletion, flow to the ischemic zone was improved but this region was still flow restricted. The flow increase during complement depletion was sufficient to allow an increased O2 utilization in the ischemic region.

References

  1. J Clin Invest. 1974 Dec;54(6):1496-508 - PubMed
  2. Circ Res. 1984 Mar;54(3):277-85 - PubMed
  3. Circ Res. 1975 Jan;36(1):34-5 - PubMed
  4. Am J Pathol. 1983 Apr;111(1):98-111 - PubMed
  5. Am J Cardiol. 1972 Oct;30(5):492-7 - PubMed
  6. Int Arch Allergy Appl Immunol. 1967;32(1):64-90 - PubMed
  7. J Clin Invest. 1978 Mar;61(3):661-70 - PubMed
  8. J Clin Invest. 1975 Sep;56(3):740-50 - PubMed
  9. J Exp Med. 1971 Apr 1;133(4):885-900 - PubMed
  10. Circ Res. 1985 Aug;57(2):223-31 - PubMed
  11. Am J Physiol. 1982 Sep;243(3):H371-8 - PubMed
  12. Circ Res. 1978 Jan;42(1):119-26 - PubMed
  13. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):129-35 - PubMed
  14. Circ Res. 1980 Sep;47(3):400-7 - PubMed
  15. Circulation. 1984 Jun;69(6):1161-70 - PubMed
  16. J Clin Invest. 1982 Aug;70(2):320-8 - PubMed
  17. J Cardiovasc Pharmacol. 1982 Mar-Apr;4(2):187-96 - PubMed
  18. Circ Res. 1985 Jul;57(1):119-30 - PubMed
  19. Circulation. 1983 May;67(5):1016-23 - PubMed
  20. Am J Cardiol. 1980 Jul;46(1):74-82 - PubMed
  21. Prostaglandins. 1982 Aug;24(2):255-66 - PubMed
  22. Microvasc Res. 1977 Sep;14(2):133-44 - PubMed
  23. Am J Cardiol. 1981 Aug;48(2):366-73 - PubMed
  24. J Clin Invest. 1980 Nov;66(5):1050-6 - PubMed
  25. Am J Cardiol. 1983 Mar 1;51(5):751-4 - PubMed
  26. Cardiology. 1979;64(5):265-79 - PubMed

Substances

MeSH terms

Publication Types

Grant support